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Introduction 
Pain is an unpleasant sensation primarily designed to avoid tissue damage. Pain is 
considered a disease that needs aggressive physician treatment. Remarkably, the number 
of patients suffering pain has been increasing up to half a billion cases per year, having 
a tremendous impact on many quality-of- life measures (1). Undertreated or poorly 
treated pain is debilitating, and results in loss of work, productivity, family crisis, 
depression and/or suicide (2,3). Currently, it is estimated that at least 50% of individuals 
seeking treatment are unsatisfied with their present pain management options. Thus, the 
economic and medical costs of inadequate pain therapy in the community are vast. 
Although pain has been traditionally considered as a unique and homogeneous 
pathology, cumulative progress has established  that pain is an extremely complex and 
dynamic process involving multiple, interrelated neurotransmitter/neuromodulator 
systems in the peripheral nervous system. Indeed, as many as 15 neurotransmitters have 
been implicated in diverse aspects of pain-processing pathways (4-6). Two major types 
of pain are widely recognized, namely neuropathic and inflammatory. Nerve injury due 
to infection, autoimmune disease, trauma, and viral infections underlie the etiology of 
neuropathic pain. Damaged fibres ectopically discharge augmenting nerve activity, 
which induces hyperexcitability at the level of the spinal cord leading to burning- like 
pain.  
At variance with neuropathic pain, inflammatory pain is produced in response to 
tissue damage (4,7). Inflammatory pain involves various painful responses resulting 
from peripheral tissue injury and/or inflammation produced by trauma, infection, 
surgery, burns or diseases with an inflammatory component. In most cases, 
inflammatory pain is mediated by pro-algesic mediators such as protons, histamine, 
cytokines, prostaglandins, neurokinins, chemokines and ATP (4,7). These molecules 
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sensitise neurons in the pain pathway (known as nociceptive neurons or nociceptors), 
either by directly modulating the sensitivity of membrane receptors or up-regulating 
intracellular signalling cascades. Nociceptors are sensitized by activation of both PKC 
and PKA pathways, which lead to phosphorylation of sensory receptors involved in 
nociceptive function (8,9). As a result, strong sensory signalling is conveyed to the 
spinal cord and subsequently to specific brain regions leading to pain sensation. This 
phenomenon is known as peripheral sensitization. In addition, synaptic and metabolic 
changes at the level of the spinal cord may occur leading to the so-called central 
sensitization which further augments the pain sensation (4,6). A major hallmark of 
inflammatory pain is thermal and mechanical hyperalgesia. Depending on the duration 
inflammatory pain is classified as acute or chronic.   
The molecular components and mechanisms involved in inflammatory pain 
transduction are now starting to be unfolded. The identification and cloning of the 
TRPV1 channel represented a significant step in the clarification of the molecular 
mechanisms underlying transduction of noxious chemical and thermal stimuli by 
peripheral nociceptors. There is growing evidence that peripheral sensitization is la rgely 
mediated by excessive excitation of TRPV1 receptors (10,11). Because of its central 
implication in hyperalgesia, the TRPV1 receptor has emerged as a key therapeutic target 
for inflammatory pain management. 
 
The TRP receptor family 
The Transient Receptor Potential (TRP) gene family is formed by more than 20 
different gene products that result in non selective cation channels that play a wide 
diversity of physiological functions. TRP channels are divided into three subfamilies: 
TRPC, TRPV and TRPM that have a common topology of six transmembrane segments 
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(S1-S6) with a pore region between the fifth and sixth segment, and cytoplasmic N- and 
C-termini. TRPV and TRPC contain two to four ankyrin domains that are thought to 
interact with the cytoskeleton (12). The first cloned TRP, a TRPC channel from 
Drosophila resulted essential for visual transduction. In the worm C. elegans, TRPC2 is 
required for transduction of pheromone-response of vomeronasal neurons [13]`. These 
are metabotropic receptors that act through G-protein coupled receptors via the 
phospholipase C pathway releasing Ca2+ from the endoplasmic reticulum trough inositol 
receptors (14). In contrast, the TRPV family are ionotropic receptors activated by 
noxious stimuli, for instance, TRPV1 gates in response to noxious temperature (³42ºC, 
vanilloids, acidic pH, and pro-algesic substances (15). Three additional TRPV channels 
have been cloned that activate at different temperature thresholds: TRPV3 from 33°C 
(16), TRPV2 to 55°C, and TRPV4 to warm temperatures and to osmolarity. Recently, 
two receptors of the TRPM family that respond to cold temperatures have been cloned. 
TRPM8 and ANKTM1 activate at 25°C and 17°C, respectively. Therefore, TRP 
channels constitute a family of sensory receptors.  
 
The TRPV1 receptor  
It has been long known that a subset of peripheral sensory neurons are excited 
by vanilloids. Cumulative studies indicate that vanilloid sensitive nociceptors are quite 
heterogeneous morphological, neurochemical and functionally. In general they are 
peptidergic, small diameter neurons that give rise to unmyelinated C fibers, with best 
correlation with Substance P, although some Ad fibers have also been found sensitive to 
vanilloid derivatives (17). TRPV1 expression has been found in dorsal root and 
trigeminal ganglia, in dorsal horn of spinal cord and caudal nucleus of spinal trigeminal 
complex by in situ hybridization, immunocytochemical analysis, and drug binding 
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assays (15,18). In dorsal root ganglia, more than 50% of neurons are TRPV1 positive. 
Immuno-specific staining of TRPV1 has been observed in the plasma membrane, Golgi 
and small clear vesicles (19). This ubiquitous intracellular distribution may be relevant 
for inflammation- induced sensitization.   
TRPV1 is also present in various brain nuclei, as well as in non-neuronal tissues, 
as exemplified by urinary bladder epithelium, smooth muscle and epidermal 
keratinocytes (20-22). TRPV1 is expressed in most of the afferent nerve fibres in the 
rodent gastrointestinal tract and some of the vagal afferents, however is still unknown 
whether it plays a role in gut sensation. TRPV1 is found not only in afferent fibres 
within the urinary bladder but also in submucosa, mucosa and epithelial cells lining the 
bladder (21,23). Thus, these observations provide a mechanism for the variety of 
functions exerted by vanilloids in non-neuronal tissues. For example, vanilloid-
mediated TRPV1 refractoriness is effective in visceral hypersensitivity. Resiniferotoxin 
and the capsaicin-analogue SDZ249-665 effectively attenuate inflammatory bladder 
hyperalgesia and visceral pain responses to intraperitoneal acetic acid in rats. Taken 
together, these findings substantiate the notion that TRPV1 plays a role in neurogenic 
inflammation and visceral pain.  
An expression-cloning strategy, using capsaicin as an specific agonist, unveiled 
the molecular identity of TRPV1. Heterologous expression of TRPV1 cDNA results in 
capsaicin-activated inward currents that recapitulate most of the functional properties of 
those described for the capsaicin and heat-activated receptors of dorsal root ganglion 
neurons. Receptor functional analysis demonstrated that TRPV1 is a non-selective 
cation channel activated by vanilloids, that exhibits a time- and Ca2+-dependent outward 
rectification followed by a long-lasting refractory state (during which the cell does not 
respond to capsaicin and other stimuli). TRPV1 is also gated at temperatures higher 
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than 42°C. In addition, mild extracellular acidic pH potentiates vanilloid receptor 
activation by noxious heat and vanilloids, while strong acidic conditions (pH<6) 
directly activates the channel. A widely held tenet is that vanilloids and acidic pH 
decrease the threshold for heat activation from noxious to non-noxious temperatures. 
Therefore, TRPV1 integrates painful physical and chemical noxious stimuli.  
Mice deficient in TRPV1 have been generated to validate TRPV1 as a 
therapeutic target. Physiological and behavioural studies of the knock out animals 
indicated a clear role of TRPV1 in thermal hyperalgesia, but not in mechanical 
hypersensitivity (24,25). Intriguingly, a modest contribution of TRPV1 to thermal 
nociception was observed, perhaps due to developmental over-expression of other 
TRPV members that contribute to the final phenotype. These studies also showed that 
TRPV1 gene ablation does not modify neuropathic pain responses. Similar conclusions 
were reached by using pharmacological tools. In vivo inhibition of TRPV1 activity by 
non-competitive antagonists attenuated thermal nociception and hyperalgesia, and 
reduced neurogenic inflammation (26). Taken together, all these findings illustrate that 
TRPV1 is a widely expressed neuronal receptor that behaves as a gateway for pain 
transduction and, in turn, validate this receptor as a key therapeutic target for pain 
management.  
 
Pharmacology of the TRPV1 receptors  
Because of its involvement in the ethiology of inflammatory pain, 
pharmacological modulation of TRPV1 is a valuable strategy to mitigate pain sensation.  
Structure-function studies have revealed that the TRPV1 receptor is a molecular entity 
with various potential drug binding sites. These properties have prompted the discovery 
of different kinds of receptor modulators with the hope that they will be of clinical use 
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to treat TRPV1 receptor dysfunction, especially in inflammatory conditions. However, 
because of the relevant role of this thermosensor in the physiology of nociceptors, 
complete abrogation of channel activity may lead to unwanted side-effects such as 
general thermal insensitivity. We next will summarize the efforts undertaken to develop 
three classes of TRPV1 modulators, namely agonists, competitive antagonists and 
channel blockers.   
 
TRPV1 agonists  
Agonists are molecules that gate the channel. Prolonged exposure of the receptor 
to the agonist, however, induces its closure by taking the protein to a desensitized state. 
Agonist-induced desensitization is dependent of the presence of extracellular Ca2+, as it 
is the process known as tachyphilaxia which is characterized by a profound run-down of 
TRPV1 responses upon repetitive agonist stimulation. Both desensitization and 
tachyphlaxia are of therapeutic value because of receptor down regulation. 
Paradoxically, agonist-induced neuronal death due to sustained receptor activation, 
especially under ischaemic conditions, is also useful for treating specific pain 
conditions.  
The best known TRPV1 agonist family is that of vanilloids. Capsaicin is the 
typical structure of one class of vanilloid compounds, the capsacinoids (Fig….). There 
are another three known chemical classes of naturally occurring vanilloids: 
resiniferanoids, unsaturated dialdehydes and triprenyl phenols, whose typical 
representative structures are resiniferatoxin (RTX), isovelleral and scutigeral 
respectively (27).  
Capsaicin is known to have three functional regions, an aromatic A region, 
where is optimal a parent homovanillyl (3-methoxy 4-hydroxybenzyl) group, a B 
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region, known as the ester o amide linker, and the aliphatic C region, where a lipophilic 
octanyl or p-chlorophenetyl moiety is associated with the highest potency. The 
homovanillyl motif and amide bond regions contain dipolar groups, which are 
implicated in hydrogen bonding interactions. Analysis of the structure-activity 
relationship of numerous capsaicin analogues suggest that these polar regions are 
essential for maintaining pungency, which could be alternatively expressed as 
maintaining the excitation of sensory neurons. In contrast, the aliphatic chain in the C 
region, which has an optimal chain length of 8-10 carbon atoms, is presumed to interact 
hydrophobically with its receptors (27). Although a receptor model has been suggested 
based on the structure-activity relationships of the capsaicin analogs, structural elements 
in TRPV1 that confer specific interactions with vanilloids have not been characterized. 
Moreover, unlike other ligand-gated channels that produce fast synaptic transmission, 
vanilloids are known to act on the TRPV1 receptor from the intracellular site (28). 
Recently, a region spanning the third transmembrane domain (S3) in TRPV1 was found 
to be essential for ligand binding, presumably by hydrophobic interactions with 
capsaicin (29). Complementary regions in TRPV1, predominantly those located in both 
cytosolic tails, have also been implicated in structuring the agonist binding site (28). 
Vanilloid compounds have been considered as potential analgesics and have 
been extensively used in medicine. Capsacinoids are traditionally indicated for relieving 
toothache. Capsaicin is a standard ingredient in a variety of over-the-counter drugs used 
worldwide to relieve muscle ache, as an example of the therapeutic value of the 
excitation that it provokes. Desensitization to capsaicin has a clear therapeutic potential 
ameliorating urinary bladder overactivity, uraemic itching associated with renal failure, 
urinary incontinence and inflammatory bowel disease. Additionally, capsaicin- induced 
neurotoxicity has already been shown to be useful in the treatment of neuropathic pain 
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such as herpes-zoster related neuropathic pain, diabetic neuropathy, and 
postmastectomy pain (27).  
A major shortcoming of therapeutic capsaicin is burning sensation and irritation 
that it produces. Structure-activity relationship studies of vanilloids have led to the 
development of more potent, orally active, vanilloid-like molecules such as SDZ-
249482 and KR-25018. However, these compounds still exhibit irritant side effects. 
Thus, a drug with long lasting desensitisation and no pungency promises to be of great 
clinical value. There are naturally and synthetic non pungent capsaicin analogs, like 
capsiate, olvanil, glycerol nonivamide, and scutigeral, but their low efficacies prevent 
their clinical development. However, ongoing clinical trials with resiniferatoxin (RTX) 
(Fig. 1), a potent capsaicin analogue isolated from Euphorbia resinifera, indicate that 
such vanilloids may in fact be useful (27).  
The specific binding of RTX to the capsaicin binding site in dorsal root ganglia 
has been demonstrated with labeled [3H]-RTX. The pharmacophoric groups of RTX 
have not yet been clearly defined, although structure-activity studies suggest that the 
C20-homovanillic moiety, the C3-keto group, and the orthoester phenyl group on ring C 
are crucial structural elements responsible for the extremely high potency of RTX. RTX 
is being developed as an ultrapotent sensory neuron desensitising agent for the 
treatment of urinary urge incontinence and the pain associated with diabetic neuropathy 
and appears to be superior to capsaicin in terms of its tolerability profile (27). The 
unquestionable therapeutic potential of RTX is seriously hampered by its limited 
availability from natural sources and the complexity of its chemical synthesis, as 
evidenced by the more than 44 reaction steps required for its total synthesis. 
Nonetheless, clinical trials with RTX are currently ongoing.   
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TRPV1 endogenous ligands  
Because TRPV1 is chemically gated the question of whether there are 
endogenous substances that gate the channel has emerged. There is cumulative evidence 
that endogenous vanilloid receptor agonists (‘endovanilloids’) exist and play a central 
role in the development inflammatory hyperalgesia. There is no doubt that these agents 
modulate the sensitivity of vanilloid receptors to thermal stimuli.  
The first endogenous compound thought to be an endovanilloid was 
anandamide, a polyunsaturated fatty acid (N-arachidonoylethanolamine), activating 
both native and recombinant rat TRPV1 receptors (Fig. 2) (30). However, anandamide 
is also considered an endocannabinoid since activates both cannabinoid CB1 and CB2 
receptors at lower concentrations than those needed to activate TRPV1. 
Capsaicin- like substances are structurally similar to some eicosanoids, 
particularly those derived from the action of 5- lipoxygenase and 12- lipoxygenase and, 
indeed, arachidonic acid has been found capable of activating the rat TRPV1, and being 
most potent 12-hydroperoxy-eicosatetraenoic acid (12-HPETE) and leukotriene B4 
(LTB4) (Fig. 2) (31). The binding site on TRPV1 is believed to occur, only by slow, 
passive diffusion. Eicosanoids are believed to function as ‘intracellular endovanilloids’, 
acting at TRPV1 receptors in the cells where they are synthesized. 
Recent studies have led to the ident ification of another compound, characterized 
as N-arachidonoyl-dopamine (NADA) proposed to act as a ‘brain endovanilloid since 
relatively abundant in some brain areas where TRPV1 is also present (Fig. 2) (32). 
NADA is an endogenous anandamide analogue several times more potent than 
anandamide on TRPV1, yet still capable of activating CB1 receptors. Thus, the 
identification and characterization of endovanilloids may provide important clues to the 
development of innovative analgesic and anti- inflammatory drugs. 
 12 
TRPV1 antagonists 
Competitive and non-competitive vanilloid antagonists are the two major classes 
of TRPV1 modulators being explored for therapeutic exploitation. The first class 
specifically seeks for compounds that bind to the agonist binding site and lock the 
channel in the closed, non-conductive state. Non-competitive antagonists, however, 
interact with additional drug binding sites located on the receptor structure. Of special 
interest are those acting as open channel blockers because they specifically recognize 
the overactivated species, i.e. pathological receptors. 
 
TRPV1 competitive antagonists 
The first competitive antagonist known, capsazepine was prepared by 
introducing a saturated seven-membered rigid ring system, which maintained a virtually 
orthogonal conformation between each N-substituent in the thiourea structure (Fig. 3). 
Tetrahydrobenzazepine and tetrahydroisoquinoline thiourea derivatives have been 
prepared as antagonists by the replacement of the p-chlorophenethyl group with 3-
acyloxy-2-benzylpropyl groups. All of them are competitive vanilloid antagonists with a 
potency ranging from 0.2 to 4 mM. When administered in animal models of 
inflammatory pain these compounds exhibit analgesic activity, although their 
therapeutic index is still low (33). In addition, they exhibit limited blockade activity on 
heat-activated channels present in the neuronal surface.  
Recently, a derivative of RTX, 5-Iodo-RTX, was shown to be a highly potent 
antagonist (IC50, 3.9 nM) of TRPV1 (Fig. 3). This compound exhibits analgesic activity 
in vivo and is currently in pre-clinical studies. As for RTX, a major drawback is the 
complexity and cost of its chemical synthesis from RTX, and its limited oral activity 
(34).  
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Taking together, the hunt for better competitive vanilloid antagonists is a major 
goal of pharmaceutical companies. We should witness in the near future the blossom of 
these efforts reflected as increasing pipelines of lead compounds for analgesic drug 
discovery.  
 
TRPV1 non-competitive antagonists 
The first non-competitive antagonist introduced as a “functional capsaicin 
antagonist” was ruthenium red, which is an inorganic polyamine acting as a 
noncompetitive antagonist that binds to the pore region of the channel (Fig. 4)  (27). 
The therapeutic use of ruthenium red is highly precluded because of its unspecific 
blockade activity.  
Arginine rich hexapeptides such as RRRRWW-NH2 block recombinant TRPV1 
channels expressed in Xenopus oocytes with submicromolar efficacy by a non-
competitive way (Fig. 4) (35). It was recently reported that they may also act through a 
competitive mechanism (36). Apart from the specific mechanism, their development as 
analgesic drugs is prevented by their pharmacological unsafety.  
A novel class of non-competitive antagonists of TRPV1 was identified from the 
screening of a peptidomimetic-based library (26) (Fig. 4). Peptidomimetic molecules 
such as N-alkylated glycines (also known as peptoids) constitute a family of non-natural 
compounds that exhibit interesting biological properties (37). Formally, peptoids result 
from the shift of the substituent present at a-carbon atom in amino acids to the adjacent 
nitrogen atom. Nevertheless, although being isomers of peptides, peptoids show 
different structural features, such as the higher degree of conformational freedom and 
the absence of CO—NH hydrogen bonds. These properties modify the steric 
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interactions leading to the secondary structure present in peptides. Moreover, contrary 
to what occurs in peptides, peptoid backbones are achiral and protease resistant.  
With regard to TRPV1, the screening of a library of trimers of N-alkylglycines 
resulted in the identification of two molecules referred to as DD161515 {N-[2-(2-
(Nmethylpyrrolidinyl)ethyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-
dichlorophenethyl)glycinamide} and DD191515 {[N-[3-
N,Ndiethylamino)propyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-
dichlorophenethyl)glycinamide} that selectively block TRPV1 channel activity with 
micromolar efficacy, rivaling that characteristic of vanilloid-related inhibitors (Fig. 4). 
These compounds appear to be non-competitive TRPV1 antagonists that recognize a 
receptor site distinct from that of capsaicin. Intraperitoneal administration of both 
trialkylglycines into mice significantly attenuated thermal nociception as measured in 
the hot plate test. It is noteworthy that these compounds eliminated pain and neurogenic 
inflammation evoked by intradermal injection of capsaicin into the animal hindpaw, as 
well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In 
contrast, responses to mechanical stimuli were not modified by either compound. 
Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic 
activity. Collectively, it seems that these trialkylglycine-based, non-competitive TRPV1 
antagonists may likely be developed into analgesics to treat inflammatory pain. Further 
progress in this exciting field is being eagerly pursued and new and more potent and 
selective hits for drug development are being identified and characterized. For example, 
hydantoin-based compounds have been identified as potent blockers of TRPV1 
channels. Notably, lead compounds that produce analgesia without affecting normal 
nociceptive responses have been developed. We await for the clinical validation of this 
sort of TRPV1 antagonists.  
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Hybrid cannabinoid-TRPV1 modulators  
Since TRPV1 is expressed in several brain regions, and next to CB1 receptors, it 
could be possible that some of the neurobehavioral effects of those endogenous 
compounds derive from the combined activation over at least, both receptors. The 
activation of these receptors often leads to similar pharmacological actions (e.g., 
antinociception, hypothermia, vasodilation, hypokinesia, and inhibition of cancer cell 
growth. Although via different mechanisms, compounds capable of simultaneously 
activating two or more of these targets may have great therapeutic potential. Those are 
the “hybrid” agonists like ‘arvanil’ (N-[3-methoxy-4-hydroxy-benzyl]-arachidonamide). 
It presents an affinity for CB1 receptors comparable to that of AEA and also activates 
TRPV1 receptors more potently than anandamide and capsaicin (Fig. 5) (38). Thus, 
arvanil is much more potent than either anandamide or capsaicin (i) as an 
antiproliferative agent for human breast cancer cells, in a fashion sensitive to both CB1 
and TRPV1 receptor antagonists, (ii) as a cannabimimetic agent in the mouse model 
‘tetrad’, (iii) as a spinal analgesic and (iv) as a relaxant of mouse vas deferens. 
However, arvanil efficacy is not well balanced between TRPV1 and CB1 receptors and 
hence, new “hybrid” CB1/TRPV1 agonists with possible therapeutic importance should 
be developed. What is of great interest is to realize that TRPV1 and cannabinoid CB1 
receptors have overlapping ligand recognition properties which may also have far 
reaching implications for vanilloid therapy. 
 
Modulators of the TRPV1 receptor signalling complex. 
An emerging concept is that ion channels are not isolated devices in the cell 
membrane, they are rather components of multiprotein complexes that play a key role in 
 16 
physiology and pathology. These macromolecular assemblies are high order signalling 
networks that balance external and internal signals giving rise to a response. 
Dysfunction of protein networks thus has deleterious consequences. These complexes 
are composed by a plethora of proteins that include receptor, adaptor, signalling, 
cytoskeletal and novel proteins. Assigned functions to these synaptic signalling 
assemblies are the biogenesis, distribution and clustering of receptors and their co-
localization with signalling proteins for an efficient transduction of external cues. Thus 
the synaptic protein complex contains a variety of potential drug targets. The molecular 
identity and organization of the TRPV1 signalling complex is still elusive. Fast-
advancing progress in this arena is uncovering the molecular identity of these elements 
which, in due turn, will be validated as therapeutic targets for drug intervention.  
Because most of these targets are protein complexes, the real challenge ahead would the 
discovery and development of small molecules that modulate protein-protein 
interactions, a yet unmet goal of current drug discovery.  
 
Perspective 
The unquestionable involvement of the TRPV1 receptor in pain transduction has 
thrust an interest on the development of antagonists of this neuronal receptor for pain 
management. This is apparently an easy task for current drug discovery platforms, 
although the real challenge is to develop antagonists that preserve the physiological 
activity of TRPV1 receptors while correcting over-active receptors. This is a condition 
to ensure normal pro-prioceptive and nociceptive responses that represent a safety 
mechanism to prevent tissue injury. Therefore, physiological constraints have to be 
included in the development and optimization of TRPV1 receptor antagonists to ensure 
their clinical utility as pain-killers.    
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Fig. Typical vanilloid structures: RTX, capsaicin, isovelleral, and scutigeral, 
representing the four known chemical cla sses of naturally occurring vanilloids, 
resiniferanoids, capsaicinoids, unsaturated dialdehydes, and triprenyl phenols, 
respectively. (Szallasi et al 1999) 
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